Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas

Area of Science:

• Hematology
• Oncology
• Clinical Therapeutics

Background:

• Systemic peripheral T cell lymphomas (PTCL) are rare, heterogeneous hematologic malignancies.
• Limited high-quality evidence complicates front-line treatment strategies for PTCL.
• Current management guidelines face several unresolved clinical controversies.

Purpose of the Study:

• To review and discuss current controversies in the front-line treatment of systemic PTCL.
• To provide insights into therapeutic decisions based on molecular subtypes and emerging agents.
• To guide clinical practice in the management of this challenging group of lymphomas.

Main Methods:

• Literature review and expert discussion on key treatment dilemmas in PTCL.
• Analysis of evidence regarding CNS prophylaxis, chemotherapy regimens (CHOP vs. CHOEP), and brentuximab vedotin.
• Evaluation of the role of stem cell transplant (SCT) and novel targeted agents.

Main Results:

• The manuscript critically examines the evidence for CNS prophylaxis and optimal chemotherapy.
• It explores the integration of brentuximab vedotin and the utility of autologous or allogeneic SCT.
• The impact of molecular subtypes (e.g., ALCL, GATA3/TBX21-related PTCL) on treatment is analyzed.

Conclusions:

• Optimizing front-line PTCL therapy requires careful consideration of chemotherapy, targeted agents, and transplant strategies.
• Personalized treatment approaches based on molecular profiling are crucial for improving outcomes.
• Further research is needed to establish definitive evidence-based guidelines for PTCL management.